NAV

L-Dilinoleoyllecithin

Identification

Generic Name
L-Dilinoleoyllecithin
DrugBank Accession Number
DB04372
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Similar Structures
Weight
Average: 782.0817
Monoisotopic: 781.562155053
Chemical Formula
C44H80NO8P
Synonyms
  • (2R)-2,3-bis[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl 2-(trimethylammonio)ethyl phosphate
  • 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine
  • 1,2-di-O-linoleoyl-sn-glycero-3-phosphocholine
  • 1,2-dilinoleoyl-sn-glycero-3-phosphocholine
  • dilinoleoylphosphatidylcholine
  • DL-PC
  • DLNPC
  • DLPC
  • L-Dilinoleoyllecithin
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UPhosphatidylcholine transfer proteinNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phosphatidylcholines. These are glycerophosphocholines in which the two free -OH are attached to one fatty acid each through an ester linkage.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Glycerophospholipids
Sub Class
Glycerophosphocholines
Direct Parent
Phosphatidylcholines
Alternative Parents
Phosphocholines / Fatty acid esters / Dialkyl phosphates / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives
show 2 more
Substituents
Aliphatic acyclic compound / Alkyl phosphate / Amine / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diacylglycero-3-phosphocholine / Dialkyl phosphate / Dicarboxylic acid or derivatives / Fatty acid ester
show 14 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
phosphatidylcholine 36:4, 1,2-di-octadecadienoyl-sn-glycero-3-phosphocholine (CHEBI:86129) / Diacylglycerophosphocholines (LMGP01010937)
Affected organisms
Not Available

Chemical Identifiers

UNII
7L874P1M1O
CAS number
998-06-1
InChI Key
FVXDQWZBHIXIEJ-LNDKUQBDSA-N
InChI
InChI=1S/C44H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h14-17,20-23,42H,6-13,18-19,24-41H2,1-5H3/b16-14-,17-15-,22-20-,23-21-/t42-/m1/s1
IUPAC Name
(2-{[(2R)-2,3-bis[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium
SMILES
CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC

References

General References
Not Available
Human Metabolome Database
HMDB0008138
PubChem Compound
5288075
PubChem Substance
46506549
ChemSpider
4450312
ChEBI
42027
PDBe Ligand
DLP
PDB Entries
1ln1 / 1ln2 / 4ews / 7dce / 7niv / 7niw / 7qp9 / 7qpa / 7qpc / 8xej

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.16e-05 mg/mLALOGPS
logP5.68ALOGPS
logP8.44Chemaxon
logS-7.4ALOGPS
pKa (Strongest Acidic)1.86Chemaxon
pKa (Strongest Basic)-6.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area111.19 Å2Chemaxon
Rotatable Bond Count40Chemaxon
Refractivity238.74 m3·mol-1Chemaxon
Polarizability93.58 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.97
Blood Brain Barrier+0.874
Caco-2 permeable-0.5297
P-glycoprotein substrateSubstrate0.5826
P-glycoprotein inhibitor INon-inhibitor0.6467
P-glycoprotein inhibitor IINon-inhibitor0.795
Renal organic cation transporterNon-inhibitor0.844
CYP450 2C9 substrateNon-substrate0.881
CYP450 2D6 substrateNon-substrate0.8149
CYP450 3A4 substrateSubstrate0.5665
CYP450 1A2 substrateNon-inhibitor0.859
CYP450 2C9 inhibitorNon-inhibitor0.8809
CYP450 2D6 inhibitorNon-inhibitor0.8972
CYP450 2C19 inhibitorNon-inhibitor0.8148
CYP450 3A4 inhibitorNon-inhibitor0.7487
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9548
Ames testNon AMES toxic0.6786
CarcinogenicityCarcinogens 0.6137
BiodegradationReady biodegradable0.9351
Rat acute toxicity2.8765 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5766
hERG inhibition (predictor II)Non-inhibitor0.7096
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-379.3038613
predicted
DarkChem Lite v0.1.0
[M-H]-289.8918
predicted
DeepCCS 1.0 (2019)
[M+H]+380.5079613
predicted
DarkChem Lite v0.1.0
[M+H]+291.78723
predicted
DeepCCS 1.0 (2019)
[M+Na]+379.0137613
predicted
DarkChem Lite v0.1.0
[M+Na]+297.46985
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Phosphatidylcholine transfer protein
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Phosphatidylcholine transporter activity
Specific Function
Catalyzes the transfer of phosphatidylcholine between membranes. Binds a single lipid molecule.
Gene Name
PCTP
Uniprot ID
Q9UKL6
Uniprot Name
Phosphatidylcholine transfer protein
Molecular Weight
24843.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52